Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Prolonged lung retention of123I-IMP in pulmonary fibrosis

  • 18 Accesses

  • 1 Citations

Abstract

We compared radiographic findings and the retention of N-isopropyl-p[123I]-iodoamphetamine (123I-IMP) in 23 patients with pulmonary fibrosis. During the 30 minutes following a rapid injection of 55.5 MBq of123I-IMP into the antecubital vein, the image of regional activity was stored. After this, 185 MBq of99mTc-MAA was injected and its image was stored to determine the region of interest. The half time (T1/2) of123I-IMP release from the lung was calculated in each pixel between 10 and 25 minutes after the injection. Chest roentgenograms were taken, and the lung field was divided into 6 portions (right upper, middle and lower, and left upper, middle and lower). A quantitative score was assigned to the radiographic finding (X-ray score). The T1/2 values in the above patients were longer than the T1/2 values in normal subjects. Prolonged T1/2 values were observed in the lung fields which had high X-ray scores. The X-ray scores and the T1/2 values in corresponding areas had a positive relation.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Gillis CN, Pitt BR: The fate of circulating amines within the pulmonary circulation.Ann Rev Physiol 44: 269–281, 1982

  2. 2.

    Junod AF: Metabolism, Production and Release of Hormones and Mediators in the Lung.Am Rev Resp Dis 112: 93–108, 1975

  3. 3.

    Vane JR: Introduction. InMetabolic Activities of the Lung. Ciba Foundation Symposium 78, New Series. Amsterdam, Excerpta Medica, pp 1–10, 1980

  4. 4.

    Philpot RM, Anderson MW, Eling TE: Uptake, accumulation and metabolism of chemicals by the lung. InMetabolic functions of the lung, edited by YS Bakhle and JR Vane. Lung biology in health and disease vol. 4, executive editor C. Lenfant. New York Marcel Dekker, Inc., p. 123, 1977

  5. 5.

    Orton TC, Anderson MW, Pickett RD, et al: Xeno-accumulation and metabolism by isolated perfused rabbit lungs.J Pharmacol Exp Ther 186: 482–497, 1973

  6. 6.

    Rahimian J, Glass EC, Touya JJ, et al: Measurement of metabolic extraction of tracers in the lung using a multiple indicator dilution technique.J Nucl Med 25: 331–337, 1984

  7. 7.

    Pistolesi M, Miniati M, Ghelarducci L, et al: A new index of lung dysfunction for clinical and experimental studies.J Nucl Med 26: P14, 1985 (abstr)

  8. 8.

    Touya JJ, Rahimian J, Grubbs DE, et al: A non-invasive procedure forin vivo assay of a lung amine endothelial receptor.J Nucl Med 26: 1302–1307, 1985

  9. 9.

    Van Zandwik N, Zwijnenburg A, Hoefnagel CA, et al: N-isopropyle-p[I-123]iodo-amphetamine, a new agent for lung imaging studies.Thorax 41: 801–803, 1986

  10. 10.

    Mena I, Thompson C, Mason G, et al: Lung firstpass extraction of N-isopropyl-I-123-p-amphetamine in patients with chronic obstructive pulmonary disease.Clin Nucl Med 9: P35, 1984 (abstr)

  11. 11.

    Ikeda H, Mariko M, Komatsu M, et al: Prolonged lung retention of123I IMP in pulmonary disease.Eur J Nucl Med 15: 646–648, 1989

  12. 12.

    Holman BL, Zimmerman RE, Schapiro JR, et al: Biodistribution and dosimetry of N-isopropyl-p-I-123-iodoamphetamine in the primate.J Nucl Med 24: 922–931, 1983

  13. 13.

    Winchell HS, Horst WD, Braun L, et al: N-isopropyl- I-123-p-iodoamphetamine: Single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain.J Nucl Med 21: 947–952, 1980

  14. 14.

    Itasaka M, Ikeda H, Yakuwa N, et al: The study of I-123 IMP lung retention by the bronchoalveolar lavage.Jpn J Nucl Med 26: 189–194, 1989

  15. 15.

    Osuda S, Kawara S, Ishibashi A, et al: Experimental study on N-isopropyl-p-iodoamphetamine lung up-take.Jpn J Nucl Med 27: 149–153, 1990

  16. 16.

    Crystal RG, Fulmer JD, Roberts WG, et al: Idiopathic pulmonary fibrosis: clinical, histologic, radio-graphic, physiologic, scintigraphic, cytologic, and biochemical aspects.Ann Int Med 85: 769–788, 1976

  17. 17.

    Crystal RG, Gadek JE, Ferrans VJ, et al: Interstitial Lung Disease: Current concepts of pathogenesis, staging and therapy.Am J Med 70: 542–568, 1981

  18. 18.

    Baldwin RM, Wu JL:In vivo chemistry of iofetamine HCL Iodine-123 (IMP).J Nucl Med 29: 122–124, 1988

  19. 19.

    Soliman MRI, Jhonson HD, Wade AE: The inter- action of inducer, inhibitors of drug metabolizing enzyme with rat liver cytochrome p450.Drug Metab Dispos 2: 87–96, 1974

  20. 20.

    Roth JR, Breakefield XO, Castiglione CM: Monoamine oxidase and cathecol-o-methyltransform activities in cultured human skin fibroblasts.Life Sci 19: 1705–1710, 1976

  21. 21.

    Hayes B, Counts DF, Kelly J, Clarke DE: A study of amine oxidases in bleomycin-induced pulmonary fibrosis.Biochem Pharmac 32: 2347–2350, 1983

  22. 22.

    Mantle TJ, Tipton KF, Garrett NJ: Inhibition of monoamine oxidase by ampetamine and related compounds.Biochem Pharmac 25: 2073–2077, 1976

Download references

Author information

Correspondence to Hideki Ikeda.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ikeda, H., Itasaka, M., Takahashi, K. et al. Prolonged lung retention of123I-IMP in pulmonary fibrosis. Ann Nucl Med 6, 147 (1992). https://doi.org/10.1007/BF03178306

Download citation

Key words

  • 123I-IMP
  • lung dynamic scintigraphy
  • pulmonary fibrosis